MXPA06013240A - Terapia adyuvante mejorada de tumores que expresan g250. - Google Patents

Terapia adyuvante mejorada de tumores que expresan g250.

Info

Publication number
MXPA06013240A
MXPA06013240A MXPA06013240A MXPA06013240A MXPA06013240A MX PA06013240 A MXPA06013240 A MX PA06013240A MX PA06013240 A MXPA06013240 A MX PA06013240A MX PA06013240 A MXPA06013240 A MX PA06013240A MX PA06013240 A MXPA06013240 A MX PA06013240A
Authority
MX
Mexico
Prior art keywords
antibody
antigen
treatment
patient
primary tumor
Prior art date
Application number
MXPA06013240A
Other languages
English (en)
Spanish (es)
Inventor
Sven Warnaar
Olaf Wilhelm
Original Assignee
Wilex Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilex Ag filed Critical Wilex Ag
Publication of MXPA06013240A publication Critical patent/MXPA06013240A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MXPA06013240A 2004-07-02 2005-06-29 Terapia adyuvante mejorada de tumores que expresan g250. MXPA06013240A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58467904P 2004-07-02 2004-07-02
PCT/EP2005/006994 WO2006002889A2 (en) 2004-07-02 2005-06-29 Improved adjuvant therapy of g250-expressing tumors

Publications (1)

Publication Number Publication Date
MXPA06013240A true MXPA06013240A (es) 2007-02-28

Family

ID=35431139

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06013240A MXPA06013240A (es) 2004-07-02 2005-06-29 Terapia adyuvante mejorada de tumores que expresan g250.

Country Status (13)

Country Link
US (1) US7691375B2 (https=)
EP (2) EP1763367A2 (https=)
JP (1) JP2008505143A (https=)
KR (1) KR101205289B1 (https=)
CN (1) CN101052416B (https=)
AU (1) AU2005259481B2 (https=)
BR (1) BRPI0512854A (https=)
CA (1) CA2566950A1 (https=)
DK (1) DK2497497T3 (https=)
ES (1) ES2641089T3 (https=)
MX (1) MXPA06013240A (https=)
RU (2) RU2371198C2 (https=)
WO (1) WO2006002889A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
CN102576025A (zh) 2009-09-18 2012-07-11 三菱化学株式会社 肝细胞癌标记物
RU2442983C1 (ru) * 2011-01-14 2012-02-20 Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы Способ прогнозирования безрецидивной выживаемости по молекулярным факторам у больных с метастазами колоректального рака в печени после ее резекции
CN104837502B (zh) 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
CA2901531C (en) 2013-02-22 2022-03-29 Wilex Ag Caix stratification based cancer treatment
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366707A1 (en) * 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoclonal antibodies to renal cell carcinoma
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US6417337B1 (en) * 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
MXPA03006992A (es) * 2001-02-07 2003-11-18 Wilex Ag Linea de celulas hibridoma g250 y su uso para la produccion de anticuerpos monoclonales.
US7381801B2 (en) 2002-02-13 2008-06-03 Ludwig Institute For Cancer Research Chimerized GM-CSF antibodies
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
RU2257200C1 (ru) * 2004-05-12 2005-07-27 Кутушов Михаил Владимирович Лекарственное средство

Also Published As

Publication number Publication date
WO2006002889A3 (en) 2006-10-05
EP2497497A1 (en) 2012-09-12
RU2371198C2 (ru) 2009-10-27
RU2009122344A (ru) 2010-12-20
DK2497497T3 (en) 2017-08-14
US7691375B2 (en) 2010-04-06
AU2005259481B2 (en) 2010-04-22
EP2497497B1 (en) 2017-06-21
US20070207157A1 (en) 2007-09-06
CN101052416B (zh) 2013-07-10
KR101205289B1 (ko) 2012-11-27
ES2641089T3 (es) 2017-11-07
CN101052416A (zh) 2007-10-10
RU2519340C2 (ru) 2014-06-10
WO2006002889A2 (en) 2006-01-12
AU2005259481A1 (en) 2006-01-12
JP2008505143A (ja) 2008-02-21
RU2007104040A (ru) 2008-08-10
CA2566950A1 (en) 2006-01-12
BRPI0512854A (pt) 2008-04-08
KR20070036085A (ko) 2007-04-02
EP1763367A2 (en) 2007-03-21

Similar Documents

Publication Publication Date Title
RU2519340C2 (ru) Улучшенная вспомогательная терапия опухолей, экспрессирующих g250
AU2018241099B2 (en) Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US9556271B2 (en) Anti-CEACAM1 recombinant antibodies for cancer therapy
KR102595561B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
RU2598710C2 (ru) Антитела к сеасам1 и способы их использования
JP4857259B2 (ja) 癌細胞増殖を阻害するための抗α５β１抗体の使用
Lam et al. G250: a carbonic anhydrase IX monoclonal antibody
CN115066260A (zh) 抗pd-1抗体在治疗恶性肿瘤中的用途
CN115052629A (zh) 抗pd-1抗体在治疗神经内分泌瘤中的用途
Herlyn et al. Initial clinical evaluation of two murine IgG2a monoclonal antibodies for immunotherapy of gastrointestinal carcinoma
CN113244386A (zh) 抗pd-1抗体在治疗肿瘤中的用途
RU2361614C2 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ ПРОТИВ α5β1 ДЛЯ ИНГИБИРОВАНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК
JP2019511515A (ja) 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法
ZA200607849B (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
HK1101348B (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation

Legal Events

Date Code Title Description
FG Grant or registration